---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264748"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:40:39.551669+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aardvark reports ARD-201 preserved lean mass, reduced weight; WE-868 shows >10% weight loss in mCRC patients

## Summary
- ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.
- In Phase 2a, ARD-101 reduced hunger (CoEQ) and showed weight control signals, well-tolerated with no serious AEs in 14 adults with obesity.
- WE-868 (OxPhos modulator) induced >10% average weight loss in mCRC patients over median 10 weeks; in DIO mice, weight loss exceeded semaglutide at 50 mg/kg.
- Aardvark plans to start Phase 2 POWER trial (weight regain prevention) for ARD-201 by end 2025; investor webinar scheduled for Nov 5.

## SEC filing metadata
- accession: 0001193125-25-264748
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312525264748/0001193125-25-264748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312525264748/ck0001774857-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264748
- JSON: https://secwatch.observer/filing/0001193125-25-264748.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.